The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

This website is intended for healthcare professionals only

Slide banner

KRAS-G12D Inhibitor (BAY 3771249)

See how this compound is being investigated across Bayer’s oncology pipeline

Explore the tumor types, areas of research, and clinical trials associated with this investigational compound.

image_sqrt

Compound Overview

KRAS-G12D Inhibitor (BAY 3771249) is a selective inhibitor of the KRAS-G12D mutant protein, a driver of oncogenic signaling in multiple tumor types.1 The KRAS-G12D mutation results in constitutive activation of KRAS-mediated signaling pathways that promote tumor cell proliferation and survival.2 By selectively targeting the mutant KRAS-G12D protein, KRAS-G12D Inhibitor (BAY 3771249) is designed to inhibit downstream signaling through pathways such as MAPK, thereby suppressing tumor growth in cancers harboring this mutation.2

This targeted approach is being investigated in tumors commonly associated with KRAS-G12D alterations, including pancreatic ductal adenocarcinoma, colorectal cancer, and non–small cell lung cancer.1

Tumor Types

Gastrointestinal cancer (colorectal, esophageal, pancreatic)
Lung cancer
Solid tumors

Area of Research

MAPK signaling

Clinical Trial

Tumor Type(s)

Phase

Status

Description

NCT Number

Lung Cancer, Solid Tumors, Gastrointestinal Cancer (Colorectal, Esophageal, Pancreatic)

I

Now Enrolling

A Phase 1a, Open-label, Multicenter, Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB548 in Participants With Advanced Solid Malignancies With a KRAS-G12D Mutation

 


 

NCT07207707

Bayer’s Oncology Pipeline Brochure

Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.

Download BrochurePDF (1.45 MB)

The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.